Preparation of kinase-biased compounds in the search for lead inhibitors of kinase targets
✍ Scribed by Justine Y.Q. Lai; Steven Langston; Ruth Adams; Rebekah E. Beevers; Richard Boyce; Svenja Burckhardt; James Cobb; Yvonne Ferguson; Eva Figueroa; Neil Grimster; Andrew H. Henry; Nawaz Khan; Kerry Jenkins; Mark W. Jones; Robert Judkins; Jeremy Major; Abid Masood; James Nally; Helen Payne; Lloyd Payne; Gilles Raphy; Tony Raynham; John Reader; Valérie Reader; Alison Reid; Parminder Ruprah; Michael Shaw; Hannah Sore; Matthew Stirling; Adam Talbot; Jess Taylor; Stephen Thompson; Hiroki Wada; David Walker
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 305 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0198-6325
No coin nor oath required. For personal study only.
✦ Synopsis
This work describes the preparation of approximately 13,000 compounds for rapid identification of hits in high-throughput screening (HTS). These compounds were designed as potential serine/threonine or tyrosine kinase inhibitors. The library consists of various scaffolds, e.g., purines, oxindoles, and imidazoles, whereby each core scaffold generally includes the hydrogen bond acceptor/donor properties known to be important for kinase binding. Several of these are based upon literature kinase templates, or adaptations of them to provide novelty. The routes to their preparation are outlined. A variety of automation techniques were used to prepare >500 compounds per scaffold. Where applicable, scavenger resins were employed to remove excess reagents and when necessary, preparative high performance liquid chromatography (HPLC) was used for purification. These compounds were screened against an 'in-house' kinase panel. The success rate in HTS was significantly higher than the corporate compound collection.
📜 SIMILAR VOLUMES
## Abstract Pharmaceutical approaches to slow the progression of Alzheimer's disease (AD) have focused primarily on reducing production or increasing clearance of amyloid β peptide (Aβ). Recent clinical trial results question the efficacy of targeting Aβ for treatment of mild to moderate AD, highli